Mano Horinaka

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Particulate Matter

Transforming Growth Factor

Dna Damage Response

Top Venues

British journal of cancer

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer 131 (2) (2024)
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer 131 (2) (2024)
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer (2024)
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer 131 (2) (2024)
Yohei Matsui, Tadaaki Yamada, Yuki Katayama, Soichi Hirai, Ryo Sawada, Yusuke Tachibana, Masaki Ishida, Hayato Kawachi, Ryota Nakamura, Naoya Nishioka, Kenji Morimoto, Masahiro Iwasaku, Mano Horinaka, Toshiyuki Sakai, Shinsaku Tokuda, Koichi Takayama
Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells. Cancer science (2024)
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer 131 (2) (2024)
Soichi Hirai, Tadaaki Yamada, Yuki Katayama, Masaki Ishida, Hayato Kawachi, Yohei Matsui, Ryota Nakamura, Kenji Morimoto, Mano Horinaka, Toshiyuki Sakai, Yoshitaka Sekido, Shinsaku Tokuda, Takayama Koichi
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. Molecular cancer therapeutics (2023)
Hisako Ono, Mano Horinaka, Mamiko Sukeno, Mie Morita, Shusuke Yasuda, Emi Nishimoto, Eiichi Konishi, Toshiyuki Sakai
Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer. Cancer science 112 (10) (2021)